1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	cotreatment	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	G.	_	_	NNP	_	_	_	_	_
9	lucidum	_	_	NN	_	_	_	_	_
10	extracts	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	GLE	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	quercetin	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	QCT	_	_	NNP	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	exerted	_	_	VBD	_	_	_	_	_
20	synergistic	_	_	JJ	_	_	_	_	_
21	antitumor	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	antiviral	_	_	JJ	_	_	_	_	_
24	activities	_	_	NNS	_	_	_	_	_
25	against	_	_	IN	_	_	_	_	_
26	SNU719	_	_	NNP	_	_	_	_	_
27	EBVaGC	_	_	NNP	_	_	_	_	_
28	cells	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Low	_	_	JJ	_	_	_	_	_
2	concentrations	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	cotreatment	_	_	NN	_	_	_	_	_
6	resulted	_	_	VBD	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	both	_	_	CC	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	synergistic	_	_	JJ	_	_	_	_	_
11	activation	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	cytotoxicity	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	SNU719	_	_	NN	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	suppression	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	tumor	_	_	NN	_	_	_	_	_
22	development	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	MKN1-EBV	_	_	NNP	_	_	_	_	_
25	xenograft	_	_	NN	_	_	_	_	_
26	mice	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	low	_	_	JJ	_	_	_	_	_
6	concentration	_	_	NN	_	_	_	_	_
7	GLE	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	QCT	_	_	NNP	_	_	_	_	_
10	reinforced	_	_	VBD	_	_	_	_	_
11	QCT-mediated	_	_	JJ	_	_	_	_	_
12	cytotoxicity	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	QCT-mediated	_	_	JJ	_	_	_	_	_
15	apoptosis	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	SNU719	_	_	NN	_	_	_	_	_
18	cells	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	addition	_	_	NN	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	activated	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	EBV	_	_	NNP	_	_	_	_	_
9	lytic	_	_	NN	_	_	_	_	_
10	gene	_	_	NN	_	_	_	_	_
11	promoter	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	upregulated	_	_	VBD	_	_	_	_	_
14	EBV	_	_	NN	_	_	_	_	_
15	genes	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	ganoderic	_	_	JJ	_	_	_	_	_
4	acid	_	_	NN	_	_	_	_	_
5	A	_	_	NNP	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	GAA	_	_	NNP	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	effective	_	_	JJ	_	_	_	_	_
12	molecule	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	GLE	_	_	NNP	_	_	_	_	_
15	also	_	_	RB	_	_	_	_	_
16	showed	_	_	VBD	_	_	_	_	_
17	similar	_	_	JJ	_	_	_	_	_
18	bioactive	_	_	JJ	_	_	_	_	_
19	features	_	_	NNS	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	QCT	_	_	NNP	_	_	_	_	_
22	like	_	_	IN	_	_	_	_	_
23	GLE	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	low	_	_	JJ	_	_	_	_	_
3	concentrations	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	GAA	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	QCT	_	_	NNP	_	_	_	_	_
9	cotreatment	_	_	NN	_	_	_	_	_
10	reinforced	_	_	VBD	_	_	_	_	_
11	QCT-mediated	_	_	JJ	_	_	_	_	_
12	cytotoxicity	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	QCT-mediated	_	_	JJ	_	_	_	_	_
15	apoptosis	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	SNU719	_	_	NN	_	_	_	_	_
18	cells	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	cotreatment	_	_	NN	_	_	_	_	_
5	activated	_	_	VBD	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	EBV	_	_	NN	_	_	_	_	_
8	lytic	_	_	NN	_	_	_	_	_
9	gene	_	_	NN	_	_	_	_	_
10	promoter	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	upregulated	_	_	VBN	_	_	_	_	_
13	EBV	_	_	NN	_	_	_	_	_
14	genes	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	like	_	_	IN	_	_	_	_	_
17	GLE	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	QCT	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	exhibit	_	_	VB	_	_	_	_	_
7	potential	_	_	JJ	_	_	_	_	_
8	anticancer	_	_	NN	_	_	_	_	_
9	properties	_	_	NNS	_	_	_	_	_
10	owing	_	_	VBG	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	its	_	_	PRP$	_	_	_	_	_
13	antiproliferative	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	growth	_	_	NN	_	_	_	_	_
16	factor	_	_	NN	_	_	_	_	_
17	suppressive	_	_	JJ	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	antioxidant	_	_	JJ	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	QCT	_	_	NNP	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	induce	_	_	VB	_	_	_	_	_
7	apoptosis	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	where	_	_	WRB	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	shown	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	reduce	_	_	VB	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	growth	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	tumors	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	inhibit	_	_	VB	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	spread	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	malignant	_	_	JJ	_	_	_	_	_
26	cells	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	inhibited	_	_	VBD	_	_	_	_	_
5	chemical	_	_	JJ	_	_	_	_	_
6	carcinogen-induced	_	_	JJ	_	_	_	_	_
7	cell	_	_	NN	_	_	_	_	_
8	transformation	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	which	_	_	WDT	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	evident	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	cell	_	_	NN	_	_	_	_	_
15	viability	_	_	NN	_	_	_	_	_
16	decreased	_	_	VBN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	ROS	_	_	NNP	_	_	_	_	_
19	generation	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	microRNA-21	_	_	NN	_	_	_	_	_
22	elevation	_	_	NN	_	_	_	_	_
23	occurred	_	_	VBD	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	cancer	_	_	NN	_	_	_	_	_
26	cells	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Besides	_	_	IN	_	_	_	_	_
2	its	_	_	PRP$	_	_	_	_	_
3	antitumor	_	_	NN	_	_	_	_	_
4	effects	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	QCT	_	_	NNP	_	_	_	_	_
7	has	_	_	VBZ	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	shown	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	have	_	_	VB	_	_	_	_	_
12	antiviral	_	_	JJ	_	_	_	_	_
13	activity	_	_	NN	_	_	_	_	_
14	through	_	_	IN	_	_	_	_	_
15	its	_	_	PRP$	_	_	_	_	_
16	anti-infective	_	_	JJ	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	anti-replicative	_	_	JJ	_	_	_	_	_
19	abilities	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	replication	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	herpes	_	_	NN	_	_	_	_	_
5	viruses	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	including	_	_	VBG	_	_	_	_	_
8	EBV	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	was	_	_	VBD	_	_	_	_	_
11	found	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	be	_	_	VB	_	_	_	_	_
14	affected	_	_	VBN	_	_	_	_	_
15	by	_	_	IN	_	_	_	_	_
16	QCT	_	_	NNP	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	EBVaGC	_	_	NNP	_	_	_	_	_
2	exhibits	_	_	VBZ	_	_	_	_	_
3	mixed	_	_	VBN	_	_	_	_	_
4	characteristics	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	both	_	_	CC	_	_	_	_	_
7	gastric	_	_	JJ	_	_	_	_	_
8	carcinoma	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	EBV	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Apoptosis	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	EBV	_	_	NN	_	_	_	_	_
4	lytic	_	_	NN	_	_	_	_	_
5	reactivation	_	_	NN	_	_	_	_	_
6	can	_	_	MD	_	_	_	_	_
7	control	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	fate	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	EBVaGC	_	_	NNP	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	where	_	_	WRB	_	_	_	_	_
15	antitumor	_	_	NN	_	_	_	_	_
16	agents	_	_	NNS	_	_	_	_	_
17	can	_	_	MD	_	_	_	_	_
18	induce	_	_	VB	_	_	_	_	_
19	apoptosis	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	antiviral	_	_	JJ	_	_	_	_	_
22	agents	_	_	NNS	_	_	_	_	_
23	can	_	_	MD	_	_	_	_	_
24	stimulate	_	_	VB	_	_	_	_	_
25	EBV	_	_	NNP	_	_	_	_	_
26	lytic	_	_	NN	_	_	_	_	_
27	reactivation	_	_	NN	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	further	_	_	RBR	_	_	_	_	_
30	aggravate	_	_	VB	_	_	_	_	_
31	cell	_	_	NN	_	_	_	_	_
32	lysis	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	QCT	_	_	NNP	_	_	_	_	_
2	exhibits	_	_	VBZ	_	_	_	_	_
3	both	_	_	DT	_	_	_	_	_
4	antitumor	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	antiviral	_	_	JJ	_	_	_	_	_
7	activities	_	_	NNS	_	_	_	_	_
8	against	_	_	IN	_	_	_	_	_
9	EBVaGC	_	_	NNP	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	dual	_	_	JJ	_	_	_	_	_
3	function	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	QCT	_	_	NNP	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	likely	_	_	JJ	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	synergistic	_	_	JJ	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	GLE	_	_	NNP	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	containing	_	_	VBG	_	_	_	_	_
4	polysaccharides	_	_	NNS	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	triterpenes	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	known	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	suppress	_	_	VB	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	proliferation	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	metastatic	_	_	JJ	_	_	_	_	_
16	potential	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	breast	_	_	NN	_	_	_	_	_
19	cancer	_	_	NN	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	inhibiting	_	_	VBG	_	_	_	_	_
23	Akt	_	_	NNP	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	AP-1	_	_	NNP	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	NF-κB	_	_	NNP	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	GLE	_	_	NNP	_	_	_	_	_
4	modulated	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	estrogen	_	_	NN	_	_	_	_	_
7	receptor	_	_	NN	_	_	_	_	_
8	signaling	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	inhibited	_	_	VBN	_	_	_	_	_
11	oxidative	_	_	JJ	_	_	_	_	_
12	stress-induced	_	_	JJ	_	_	_	_	_
13	invasiveness	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	breast	_	_	NN	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Consistent	_	_	JJ	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	results	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	previous	_	_	JJ	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	breast	_	_	NN	_	_	_	_	_
10	cancer	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	our	_	_	PRP$	_	_	_	_	_
13	study	_	_	NN	_	_	_	_	_
14	showed	_	_	VBD	_	_	_	_	_
15	that	_	_	IN	_	_	_	_	_
16	GLE	_	_	NNP	_	_	_	_	_
17	enhanced	_	_	VBD	_	_	_	_	_
18	both	_	_	CC	_	_	_	_	_
19	QCT-mediated	_	_	JJ	_	_	_	_	_
20	apoptosis	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	EBV-lytic	_	_	JJ	_	_	_	_	_
23	reactivation	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	effects	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	GLE	_	_	NNP	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	evident	_	_	JJ	_	_	_	_	_
7	at	_	_	IN	_	_	_	_	_
8	low	_	_	JJ	_	_	_	_	_
9	concentrations	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	QCT	_	_	NNP	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	QCT	_	_	NNP	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	enhanced	_	_	VBD	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	GLE-mediated	_	_	JJ	_	_	_	_	_
8	upregulation	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	EBV	_	_	NNP	_	_	_	_	_
12	gene	_	_	NN	_	_	_	_	_
13	expression	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Similarly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	effects	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	QCT	_	_	NNP	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	evident	_	_	JJ	_	_	_	_	_
9	at	_	_	IN	_	_	_	_	_
10	low	_	_	JJ	_	_	_	_	_
11	concentrations	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	GLE	_	_	NNP	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	results	_	_	NNS	_	_	_	_	_
5	suggested	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	GLE	_	_	NNP	_	_	_	_	_
8	enhanced	_	_	VBD	_	_	_	_	_
9	QCT-mediated	_	_	JJ	_	_	_	_	_
10	apoptosis	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	whereas	_	_	IN	_	_	_	_	_
13	QCT	_	_	NNP	_	_	_	_	_
14	increased	_	_	VBD	_	_	_	_	_
15	GLE-mediated	_	_	JJ	_	_	_	_	_
16	EBV	_	_	NN	_	_	_	_	_
17	lytic	_	_	NN	_	_	_	_	_
18	reactivation	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Mycotherapy	_	_	NN	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	benefits	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	where	_	_	WRB	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	improves	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	overall	_	_	JJ	_	_	_	_	_
11	response	_	_	NN	_	_	_	_	_
12	rate	_	_	NN	_	_	_	_	_
13	during	_	_	IN	_	_	_	_	_
14	cancer	_	_	NN	_	_	_	_	_
15	treatment	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	enhances	_	_	VBZ	_	_	_	_	_
18	immunity	_	_	NN	_	_	_	_	_
19	owing	_	_	VBG	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	stimulation	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	T	_	_	NN	_	_	_	_	_
25	cell	_	_	NN	_	_	_	_	_
26	proliferation	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	reduces	_	_	VBZ	_	_	_	_	_
29	some	_	_	DT	_	_	_	_	_
30	chemotherapy-associated	_	_	JJ	_	_	_	_	_
31	adverse	_	_	JJ	_	_	_	_	_
32	events	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	such	_	_	JJ	_	_	_	_	_
35	as	_	_	IN	_	_	_	_	_
36	nausea	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	insomnia	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Medicinal	_	_	JJ	_	_	_	_	_
2	mushrooms	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	mainly	_	_	RB	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	used	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	Asian	_	_	JJ	_	_	_	_	_
9	countries	_	_	NNS	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	hundreds	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	years	_	_	NNS	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	treatment	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	infectious	_	_	JJ	_	_	_	_	_
19	diseases	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	More	_	_	RBR	_	_	_	_	_
2	recently	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	they	_	_	PRP	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	used	_	_	VBN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	cancer	_	_	NN	_	_	_	_	_
10	treatment	_	_	NN	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	adjuncts	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Importantly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	extensive	_	_	JJ	_	_	_	_	_
7	clinical	_	_	JJ	_	_	_	_	_
8	history	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	safe	_	_	JJ	_	_	_	_	_
11	use	_	_	NN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	single	_	_	JJ	_	_	_	_	_
14	agents	_	_	NNS	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	combination	_	_	NN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	chemotherapy	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	GLE	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	intensively	_	_	RB	_	_	_	_	_
5	combined	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	mycotherapy	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	treatment	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	broad-spectrum	_	_	JJ	_	_	_	_	_
13	cancers	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	GLE	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	shown	_	_	VBN	_	_	_	_	_
4	antitumor	_	_	NN	_	_	_	_	_
5	activities	_	_	NNS	_	_	_	_	_
6	against	_	_	IN	_	_	_	_	_
7	breast	_	_	NN	_	_	_	_	_
8	cancer	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	bladder	_	_	NN	_	_	_	_	_
11	cancer	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	prostate	_	_	NN	_	_	_	_	_
14	cancer	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	colorectal	_	_	JJ	_	_	_	_	_
17	cancer	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	others	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	tumor	_	_	NN	_	_	_	_	_
3	inhibitory	_	_	JJ	_	_	_	_	_
4	effects	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	GLE	_	_	NNP	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	attributed	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	disruption	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	proliferation	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	metastasis	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	cancer	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	fact	_	_	NN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	EBV	_	_	NNP	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	initiator	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	gastric	_	_	JJ	_	_	_	_	_
12	carcinoma	_	_	NN	_	_	_	_	_
13	should	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	considered	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	treatment	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	EBVaGC	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	EBV	_	_	NNP	_	_	_	_	_
2	should	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	eliminated	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	reduce	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	risk	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	EBVaGC	_	_	NNP	_	_	_	_	_
11	relapse	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	QCT	_	_	NNP	_	_	_	_	_
6	strongly	_	_	RB	_	_	_	_	_
7	induced	_	_	VBD	_	_	_	_	_
8	EBV	_	_	NNP	_	_	_	_	_
9	lytic	_	_	NN	_	_	_	_	_
10	reactivation	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	synergistic	_	_	JJ	_	_	_	_	_
3	effects	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	GLE	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	QCT	_	_	NN	_	_	_	_	_
9	cotreatment	_	_	NN	_	_	_	_	_
10	might	_	_	MD	_	_	_	_	_
11	enhance	_	_	VB	_	_	_	_	_
12	QCT-mediated	_	_	JJ	_	_	_	_	_
13	apoptosis	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	GLE-mediated	_	_	JJ	_	_	_	_	_
16	EBV	_	_	NN	_	_	_	_	_
17	lytic	_	_	JJ	_	_	_	_	_
18	reactivation	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	QCT-supplemented	_	_	VBN	_	_	_	_	_
4	GLE	_	_	NNP	_	_	_	_	_
5	might	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	used	_	_	VBN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	medicinal	_	_	JJ	_	_	_	_	_
11	food	_	_	NN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	dual	_	_	JJ	_	_	_	_	_
15	function	_	_	NN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	antitumor	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	antiviral	_	_	JJ	_	_	_	_	_
21	agent	_	_	NN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	EBVaGC	_	_	NNP	_	_	_	_	_
24	treatment	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	author	_	_	NN	_	_	_	_	_
4	’s	_	_	POS	_	_	_	_	_
5	knowledge	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	this	_	_	DT	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	first	_	_	JJ	_	_	_	_	_
11	study	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	report	_	_	VB	_	_	_	_	_
14	that	_	_	IN	_	_	_	_	_
15	QCT-supplemented	_	_	VBN	_	_	_	_	_
16	GLE	_	_	NN	_	_	_	_	_
17	might	_	_	MD	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	effective	_	_	JJ	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	treating	_	_	VBG	_	_	_	_	_
22	EBVaGC	_	_	NNP	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	synergistic	_	_	JJ	_	_	_	_	_
3	antitumor	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	antiviral	_	_	JJ	_	_	_	_	_
6	effects	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	supported	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	both	_	_	DT	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	vivo	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	in	_	_	FW	_	_	_	_	_
15	vitro	_	_	NN	_	_	_	_	_
16	studies	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Hence	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	combined	_	_	VBN	_	_	_	_	_
5	use	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	GLE	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	QCT	_	_	NNP	_	_	_	_	_
10	could	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	beneficial	_	_	JJ	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	cancer	_	_	NN	_	_	_	_	_
15	treatment	_	_	NN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	alleviating	_	_	VBG	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	toxicity	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	conventional	_	_	JJ	_	_	_	_	_
22	chemotherapy	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	improving	_	_	VBG	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	immune	_	_	JJ	_	_	_	_	_
27	function	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	more	_	_	JJR	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	still	_	_	RB	_	_	_	_	_
7	needed	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	further	_	_	RBR	_	_	_	_	_
10	elucidate	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	molecular	_	_	JJ	_	_	_	_	_
13	mechanisms	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	direct	_	_	JJ	_	_	_	_	_
17	antitumor	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	antiviral	_	_	JJ	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	QCT-supplemented	_	_	VBN	_	_	_	_	_
23	GLE	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_

